


Points of Distinction



-SAMUEL H. GOLTER

City of Hope® is a world leader in cancer research, treatment and prevention. Physicians here partner with scientists to transform laboratory breakthroughs into treatments that outsmart cancer, as well as diabetes and other life-threatening diseases. With locations in California, Arizona, Illinois and Georgia, our team of more than 12,000 is united by our desire to find cures and save lives.

Our recent expansion has put a City of Hope care facility within driving distance of 86 million people — more than a quarter of the U.S. population.



INSTITUTIONAL DISTINCTIONS



- One of only 56 comprehensive cancer centers in the nation, we received the highest rating possible by the National Cancer Institute (NCI).
- We've been ranked among the nation's "Best Hospitals" for cancer by U.S. News & World Report for 17 consecutive years and among the top 10 for the last two.
- Our nursing team has achieved Magnet® recognition from the American Nurses Credentialing Center for our commitment to outstanding health care delivery and patient

- outcomes. Only 9% of hospitals have earned Magnet recognition.
- We're a founding member of the National Comprehensive Cancer Network, meaning our research and treatment protocols advance care throughout the nation.



We have conducted more than 16,000 robotic surgeries for prostate, kidney, colon, liver, bladder, gynecologic, oral and other cancers.

- We were awarded more than \$214.2 million in research grants in FY22.
- We've earned the highest rating four stars — from the nation's leading watchdog, Charity Navigator, reflecting our sound fiscal management, financial growth and stability.
- We were awarded the highest level of accreditation by the American College of Surgeons Commission on Cancer for our exceptional level of cancer care, "Three-Year With Commendation." This is the second consecutive time that we have received this prestigious rating.

A RECORD OF INNOVATION

- Numerous breakthrough cancer drugs, including Herceptin, Erbitux, Rituxan and Avastin, are based on technology spearheaded here and are saving lives worldwide.
- Millions of people with diabetes benefit from synthetic human insulin, developed through research conducted here.
- We were a pioneer in bone marrow and stem cell transplants — and our program is now one of the largest, most successful programs of its kind in the U.S.



We blazed the trail in **CAR T cell therapy**, including being the first to use it locally in the brain through direct injection to the tumor site and the first to use CAR T to treat patients with the rare disease blastic plasmacytoid dendritic cell neoplasm. We have recently opened CAR T trials in prostate and ovarian cancer.



We are a leader in immune effector cell therapies such as CAR T cell therapy, having treated more than 1,200 patients to date.

SPEED, EFFICIENCY AND COLLABORATION

 Our research facilities set us apart. We have three manufacturing facilities on campus that manufacture biologic and chemical compounds that meet strict good manufacturing practice (GMP) standards. This infrastructure helps us quickly turn breakthrough discoveries into lifesaving therapies,



We offer the most cancer clinical trials in California
— more than 850 each year, enrolling 7,000+ patients

 We hold more than 450 patent portfolios and submit nearly 50 applications per year to the Food and Drug Administration for investigational new therapies. These numbers are exceptionally large for an organization of our size.



Beckman Research Institute of City of Hope was the first of five Beckman Institutes in the U.S., which together have fueled scientific advances for more than a generation.

SCIENCE THAT IS SAVING LIVES

 Our researchers are investigating ways to harness the body's natural defenses to fight cancer. These therapies include CAR T cell therapy, bispecific and monoclonal antibodies, natural killer cells and checkpoint inhibitors. Studies are focused on engaging every stage of the immune response to defeat blood, breast, brain, skin, ovarian, prostate and other cancers.



We have performed nearly 19,000 bone marrow and stem cell transplants.



- Our Center for Precision Medicine's INSPIRE
 (Implementing Next-generation Sequencing
 for Precision Intervention and Risk Evaluation)
 study makes comprehensive genetic testing
 available to every person seen for care —
 regardless of the diagnosis. Since launching in
 2020, INSPIRE has enrolled over 15,000 people.
- We acquired Translational Genomics Research Institute (TGen) to make precision medicine a reality for patients. TGen's genomic insights augment the level of care available to City of Hope patients, helping to create highly personalized treatment plans.

CARING FOR THE WHOLE PERSON



Our Department of Supportive Care Medicine was the first in the United States to fully integrate supportive care specialties into patients' clinical care and is one of the largest programs of its kind today. It provides cancer patients with comprehensive physical, psychological, social and practical support services, including psychological and spiritual counseling, pain management, physical and occupational therapy and integrative medicine, such as yoga, massage and meditation.



Compassion is at the heart of our approach. We care for the whole person, not just the body.



• We recently launched the **Cherng Family Center for Integrative Oncology,** a first-of-its-kind national program that will bring together Eastern and Western treatment methods.

BEYOND THE STUDY OF CANCER

 By investigating the molecular mechanisms of diabetes complications, our scientists are helping to develop new treatments for them.



- We also are studying the use of various immunotherapies, some based on techniques borrowed from the oncology space, to treat type 1 diabetes.
- We are a national leader in islet cell transplantation, which has the potential to reverse type 1 diabetes. In addition, we provide islet cells for research at other institutions throughout the U.S.
- Our scientists pioneered the application of blood stem cell transplants to treat patients with HIV and AIDS-related lymphoma. Our researchers used a new form of gene therapy to achieve the first long-term persistence of anti-HIV genes in patients with AIDS-related lymphoma. This treatment ultimately may cure not only lymphoma, but also HIV/AIDS.
- In 2022, we placed an HIV patient with leukemia into remission, one of only five such patients in the world.
- During the pandemic, we developed a
 COVID-19 vaccine specifically targeted to immunocompromised patients.

PHILANTHROPY ALLOWS US TO HELP MORE PEOPLE — FASTER

Philanthropy is a vital accelerator of high-impact research across the enterprise, advancing innovative approaches and clinical trials in hematological cancers, precision medicine, novel cellular therapies, diabetes, supportive care medicine and health equity. It also plays a critical role in our ability to recruit and support the leading clinicians, gifted scientists and skilled teams who stand behind the cures we deliver, the discoveries we make and the hope we bring.

THE COLLECTIVE IMPACT



\$200+ million

raised every year to fight cancer and diabetes

\$1+billion

total raised by corporate and industry partners





30,000+

participants in volunteer-led fundraising events

100,000+

individual donors annually





25,000+

volunteers

